Alimta ® (pemetrexed for injection)

This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information.For current prescribing information for all Lilly products, including Summaries of Product Characteristics, Patient Information Leaflets and Instructions for Use, please visit: (England, Scotland, Wales) or (Northern Ireland).

Alimta® (pemetrexed): Infusion Via Central Line Versus Peripheral IV

Lilly does not have any information available regarding infusion of pemetrexed via a central line versus peripheral IV.

Detailed Information

Pemetrexed must be administered as an IV infusion.1

Lilly has not studied central line vs peripheral IV administration of pemetrexed.2

Clinical circumstances may be present which prevent a patient from having peripheral IV access. In the case of central line access only, the treating physician should make an appropriate clinical decision considering the risk/benefit, given that there is no information available regarding administration of pemetrexed via a central line IV.2


1. Alimta [summary of product characteristics]. Eli Lilly Nederland B.V., The Netherlands

2. Data on file, Eli Lilly and Company and/or one of its subsidiaries.


IV = intravenous

Lilly = Eli Lilly and Company

Date of Last Review: 04 September 2020

Contact Lilly

Call or Email us

If you want to ask a Medical Information question or you want to report an adverse event or product complaint you can call us or email us at

Available Mon - Fri, 10am - 4pm, excluding Bank Holidays

Or you can

Chat with Us

Click to Chat is Offline

If you have a question, you can chat online with a Lilly Medical Information professional.

Submit a request